Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549
In development
Reference number: GID-TA11722
Expected publication date:
To appraise the clinical and cost effectiveness of Anitocabtagene autoleuce (CART-ddBCMA) within its marketing authorisation for
treating multiple myeloma